STOCK TITAN

Arcus Bioscience SEC Filings

RCUS NYSE

Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Arcus Biosciences’ SEC documents can stretch beyond 300 pages, packed with clinical trial endpoints, ATP-adenosine data, and collaboration milestones—details many investors struggle to decode. If you have ever asked, “How do I find Arcus Biosciences’ quarterly earnings report 10-Q filing?” or “Where are Arcus Biosciences insider trading Form 4 transactions recorded?”, this page is designed for you.

Stock Titan’s AI reads every new submission to EDGAR in seconds, delivering real-time filing updates, plain-English summaries, and keyword search across the full library. Need the Arcus Biosciences annual report 10-K simplified? We highlight pipeline progress, cash runway, and risk factors. Curious about material news? Our engine breaks down Arcus Biosciences 8-K material events explained and alerts you the moment they post. You can also monitor Arcus Biosciences Form 4 insider transactions real-time to see when scientists or executives buy or sell shares.

Because Arcus’ value hinges on immuno-oncology breakthroughs, we map each filing to specific questions investors ask: Which trial reached Phase 2? How large is the R&D spend quarter-over-quarter? What did the Arcus Biosciences proxy statement executive compensation reveal about retention of key researchers? Whether you’re tracking Arcus Biosciences earnings report filing analysis for revenue from partners or simply understanding Arcus Biosciences SEC documents with AI, our platform saves hours of manual work. Explore every 10-K, 10-Q, 8-K, S-3, and Arcus Biosciences insider trading Form 4 transactions—all explained simply and updated the instant they hit EDGAR.

Rhea-AI Summary

Arcus Biosciences (RCUS) reported first overall survival results from Arm A1 of its Phase 2 EDGE-Gastric study in advanced gastric, GEJ, or esophageal adenocarcinoma. At data cutoff on March 3, 2025, all 41 treated patients were evaluated with a median follow-up of 26.4 months.

The regimen of domvanalimab plus zimberelimab and chemotherapy showed median overall survival of 26.7 months (90% CI: 18.4, NE) in the overall population and 26.7 months (90% CI: 19.5, NE) in PD‑L1 positive patients. In PD‑L1 high patients, median overall survival was not estimable (90% CI: 17.4, NE). The 24‑month overall survival rate was 50.2% (90% CI: 36.3, 62.6). Median progression‑free survival was 12.9 months (90% CI: 9.8, 14.6), and confirmed objective response rate was 59% (24/41; 90% CI: 45%, 72%).

No unexpected safety signals were observed. The safety profile was generally well tolerated and consistent with anti‑PD‑1 plus chemotherapy. Immune‑mediated TEAEs occurred in 9 patients (22%), and infusion‑related reactions in 3 patients (7%).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Arcus Biosciences, Inc. filed a Form 144 reporting a proposed sale of 100,583 shares of common stock through J.P. Morgan Securities LLC on 10/06/2025. The filing shows the shares were acquired and paid for on 10/06/2025 via a stock option exercise with payment in cash. The aggregate market value listed for the shares to be sold is 1,342,783 and the total shares outstanding are 106,430,976, which implies the block represents roughly 0.095% of outstanding shares. No other sales in the past three months were reported and no seller name is disclosed in the public sections of the form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
current report
-
Rhea-AI Summary

Arcus Biosciences (RCUS) insider sale by Chief Accounting Officer. The reporting person sold 2,831 shares of Arcus common stock on 09/29/2025 at $13.00 per share, leaving beneficial ownership of 27,363 shares after the transaction. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. The filing was executed by an attorney-in-fact on 09/30/2025. This report discloses a planned, executed disposition by a senior financial officer that reduced their holdings by approximately 9.4% of their pre-sale position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Arcus Biosciences insider sale by Chief Accounting Officer. Alexander Azoy, listed as Chief Accounting Officer, reported a sale of 1,579 shares of Arcus Biosciences (RCUS) on 09/05/2025. The filing shows these shares were originally purchased on 05/30/2025 through the company Employee Stock Purchase Plan and were sold under a Rule 10b5-1 trading plan adopted 06/06/2025. The weighted-average sale price reported is $11.8797, with individual sale prices ranging from $11.55 to $12.22. After the reported sale, the reporting person beneficially owned 30,194 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Arcus Biosciences, Inc. (RCUS) notice reports a proposed sale of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025. The shares have an aggregate market value of $18,253.24 and the issuer has 106,430,976 shares outstanding. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 09/05/2025. Payment for the acquisition was cash. The filer states there were no securities sold by the person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
quarterly report

FAQ

What is the current stock price of Arcus Bioscience (RCUS)?

The current stock price of Arcus Bioscience (RCUS) is $18.05 as of October 21, 2025.

What is the market cap of Arcus Bioscience (RCUS)?

The market cap of Arcus Bioscience (RCUS) is approximately 1.9B.
Arcus Bioscience

NYSE:RCUS

RCUS Rankings

RCUS Stock Data

1.86B
69.33M
34.73%
67.52%
9.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD